What is the global market size of Cell Therapy Market?

Cell Therapy Market size was valued at USD 18.92 billion in 2021 and is poised to grow from USD 21.6 billion in 2022 to USD 71.07 billion by 2030, growing at a CAGR of 14.15% in the forecast period (2023-2030).

Who are the key vendors in the Global Cell Therapy Market?

Companies are getting FDA permission for stem cell treatment for a variety of disorders and infections. For example, in September 2020, the FDA granted Stemedica Cell Technologies, Inc. Investigational New Drug permission to undertake phase II studies of intravenously delivered allogeneic MSCs in covid-19 patients. Ischemic-tolerant MSCs have various characteristics that make them an appealing potential biological treatment for COVID-19, including immunomodulatory effects, limited immunogenicity, and the ability to inhibit excessive pro-inflammatory responses. 'Novartis AG', 'Kite Pharma Inc. (a subsidiary of Gilead Sciences Inc.)', 'Vericel Corporation', 'Takeda Pharmaceutical Company Limited', 'Bluebird Bio Inc.', 'Celgene Corporation (now part of Bristol Myers Squibb)', 'Fate Therapeutics Inc.', 'Spark Therapeutics Inc. (a subsidiary of Roche Holding AG)', 'Osiris Therapeutics Inc. (a subsidiary of Smith & Nephew plc)', 'Fibrocell Science Inc. (now part of Castle Creek Pharmaceuticals LLC)', 'Mesoblast Limited', 'TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited)', 'Sangamo Therapeutics Inc.', 'Celyad Oncology SA', 'Gamida Cell Ltd.', 'JCR Pharmaceuticals Co. Ltd.', 'Cytori Therapeutics Inc.', 'Athersys Inc.', 'DiscGenics Inc.', 'BrainStorm Cell Therapeutics Inc.'.

What is the key driver of Global Cell Therapy Market?

The demand for novel, better medicines for illnesses like cancer and CVD has led to a rise in general research efforts, as well as financing for cell-based research.

What is the key market trend for Global Cell Therapy Market?

The expansion of the cell therapy market was aided by the growing frequency of chronic illnesses. Chronic illness is defined as a condition that lasts one year or more and requires medical treatment, affects everyday activities, or both, according to the US Centers for Disease Control and Prevention (CDC). It includes heart disease, cancer, diabetes, and Parkinson's disease. Patients with spinal cord injuries, type 1 diabetes, Parkinson's disease (PD), heart disease, cancer, and osteoarthritis may benefit from stem cells.

Which region accounted for the largest share in Global Cell Therapy Market?

In 2020, North America is expected to have the biggest market share of 42.0%. The existence of a significant number of institutions and institutes involved in stem cell treatment research and development accounts for the region's large share. Five of the eight top colleges in the world are situated in the United States, including Stanford University's Institute for Stem Cell Biology and Regenerative Medicine, Harvard University's Harvard Stem Cell Institute, and Yale University's Yale Stem Cell Center. Over the projected period, the market for cell therapy in the Asia Pacific is expected to develop at a profitable rate. The growing investment by developers and customers in self-education for sophisticated medical therapies is expected to enhance the income generated by the region's expanding economies. In Asian nations, there are a number of stem cell consortiums whose goal is to ensure that R&D activities are well-coordinated and targeted. Furthermore, because of the legal framework's flexibility, patients from Western nations have been spotted migrating to Asian countries for treatment.

Cell Therapy Market Size, Share, Growth Analysis, By Cell Type(Stem Cell (Bone Marrow, Blood, Umbilical Cord-Derived, Adipose-Derived Stem Cell), By Therapy Type(Autologous, Allogeneic), By End User(Hospitals & Clinics, Academic & Research Institutes), By Therapeutic Area(Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2061 | Region: Global | Published Date: July, 2024
Pages: 157 | Tables: 132 | Figures: 77

Cell Therapy Market Regional Insights

North America is projected to account for a dominant share of the global cell therapy market in the future. High investments in medical R&D, the presence of key biotechnology companies, and supportive government funding are key factors that are estimated to help the high market share of this region. Canada and the United States are slated to be the top markets for cell therapy companies in this region. High demand for cell therapies to treat chronic diseases will also favor market growth in this region.

Asia Pacific is expected to emerge as the fastest-expanding market for cell therapies in the world going forward. Growing awareness regarding benefits of cell therapies, high investments in healthcare infrastructure development, and rising acceptance of cell therapies are top factors that will create new opportunities for cell therapy companies in the future. Japan, China, and India are slated to be the key markets in this region.

Cell Therapy Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Cell Therapy Market size was valued at USD 3.9 Billion in 2022 and is poised to grow from USD 6.7 Billion in 2023 to USD 190.91 Billion by 2031, growing at a CAGR of 52% during the forecast period (2024-2031).

Cell therapy companies can also benefit from government grants and supportive initiatives launched to help boost medical R&D. Cell therapy providers should invest heavily in research to boost innovation and stand out from the competition. New companies can penetrate the market with hefty capital raise and innovative approach to compete with established market players. Integration of advanced technologies to fast-track development will also be a key strategy for cell therapy companies in the future. 'Thermo Fisher Scientific, Inc. (US) ', 'Merck KGaA (Germany) ', 'Danaher Corporation (US) ', 'Becton, Dickinson, and Company (US) ', 'Lonza Group (Switzerland) ', 'Sartorius AG (Germany) ', 'Nkarta, Inc. (US) ', 'Aurion Biotech (US) ', 'S. BIOMEDICS (Europe) ', 'MEDIPOST (South Korea) ', 'Anterogen Co., Ltd. (South Korea) ', 'JW Therapeutics (China) ', 'JCR Pharmaceuticals Co., Ltd. (Japan) ', 'Johnson & Johnson Services, Inc (US) ', 'Bristol-Myers Squibb Company (US) ', 'Gilead Sciences, Inc. (US) ', 'Novartis AG (Switzerland) ', 'Intellia Therapeutics (US) ', 'Iovance Therapeutics (US) ', 'CRISPR Therapeutics (Switzerland)'

Rapidly increasing demand for personalized medicine around the world is boosting the adoption of novel cell therapies as they are crucial in targeting specific characteristics of an individual. Cell therapies also help in identifying the efficacy of therapy on an individual to reduce the risk of rejection.

CAR-T Cell Therapy: The prevalence of cancer has increased exponentially on a global level and so has the need for novel treatments as well. CAR-T (Chimeric Antigen Receptor T-cell) therapy is emerging as a popular immunotherapy for the treatment of various cancers, companies can capitalize on this trend to maximize their business scope in the long run.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Cell Therapy Market Regional Insights

Cell Therapy Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Cell Therapy Market?

Who are the key vendors in the Cell Therapy Market?

What is the key driver of Cell Therapy Market?

What is the key market trend for Cell Therapy Market?

Which region accounted for the largest share in Cell Therapy Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300